Australia's most trusted
source of pharma news
Wednesday, 05 November 2025
Posted 3 November 2025 AM
The second last round of PBS listings for 2025 has seen 12 drugs win reimbursement from November, seven of them new listings.
Eligible Australians living with advanced unresectable hepatocellular carcinoma (HCC), the most common type of primary liver cancer, can now access AstraZeneca's Imfinzi and Imjudo duo - the first dual immunotherapy combination option funded on the PBS.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.